Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Curetis AG Strengthens Commercial Team and Expands Distribution Network

Published: Monday, March 11, 2013
Last Updated: Monday, March 11, 2013
Bookmark and Share
Appointment of Helmut Hilbert as Head of Business Development.

Curetis AG has announced the appointment of Helmut Hilbert as Head of Business Development and the expansion of its distribution network into Belgium and Luxembourg by closing a distribution agreement with ELITech BNL (former Lucron Bioproducts), an ELITech Group company.

In order to strengthen its global commercial operations, Curetis has hired Dr. Helmut Hilbert, formerly Associate Director Corporate Business Development at Qiagen, as Head of Business Development.

Helmut Hilbert has more than ten years of business and corporate development experience and built a strong track record in licensing, mergers and acquisitions, technology transfer and innovation management.

At Qiagen, he was responsible for scouting novel technologies as well as evaluating potential acquisition targets and investment opportunities, including contract negotiation, due diligences and post-merger integration.

Moreover, Curetis has selected ELITech BNL as its Belgian and Luxembourgian distribution partner. ELITech BNL (former Lucron Bioproducts) has a long-standing track record as a distributor of quality diagnostic products and research supplies in the Benelux.

Among others, the company supported the market entry of Cepheid into these countries.

Acquired by the global in vitro diagnostics distributor ELITech Group in 2010, ELITech BNL is part of an extensive commercial network covering France, Italy, the UK and the rest of the world.

“Having built a successful business for Cepheid and the GeneXpert system in the Benelux, we are excited about the opportunity presented by the Curetis Unyvero Solution,” said Frank Loots, General Manager of ELITech BNL.

Loots continued, “We are planning a commercial roll-out and market introduction phase here in Belgium and in Luxembourg to begin with leading clinicians and institutions in our territories.”

“With the appointment of Helmut Hilbert as Head of Business Development and the distribution agreement with ELITech, we continue our accelerated commercial development progress,” said Oliver Schacht, CEO of Curetis.

Schacht continued, “The growing awareness for the Unyvero™ System allows us to attract experienced employees and renowned corporate partners and to expand our operations. We are in the process of growing our business in the Middle East with additional placements in Dubai, Saudi Arabia and Qatar over the next couple of months. In addition, our customer order book continues to expand significantly - we currently have a waiting list of more than fifty top-tier institutions worldwide.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Curetis AG Successfully Increases Series A Financing Round to EUR 24.5 Million
CD-Venture joins strong syndicate of existing VC investors.
Wednesday, May 18, 2011
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
ReadCoor Launched to Commercialize 3D Sequencing Tech
ReadCoor will leverage the Wyss Institute’s method for simultaneously sequencing and mapping RNAs within cells and tissues to advance development of diagnostics.
Crispr Toolbox Expanded By Protein
Researchers have shown a newly discovered CRISPR protein has two distinct RNA cutting activities.
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Over Two-Thirds of Cervical Cancer Deaths Prevented
Cervical screening prevents 70% of cervical cancer deaths and if all eligible women regularly attended screening this would rise to 83%.
Detecting Bacterial Infections in Newborns
Researchers tested an alternative way to diagnose bacterial infections in infants—by analyzing RNA biosignatures from a small blood sample.
Case for Liquid Biopsies Builds in Advanced Lung Cancer
Study addresses unmet need for better, non-invasive tests called out in recent "Moonshot" blue ribbon panel report
Mechanisms of Parkinson’s Pathology
Defects that lead to cells’ failure to decommission faulty mitochondria cause nerve cells to die, triggering the symptoms of Parkinson’s disease.
Genetic Misdiagnoses of Heart Condition
Analysis found several genetic variations previously linked with a heart condition were harmless, leading to condition misdiagnosis.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!